| 严 爽,王 礼,吴月兵.酪氨酸激酶抑制剂抑制非小细胞肺癌脑转移[J].中国肿瘤,2013,22(11):918-921. |
| 酪氨酸激酶抑制剂抑制非小细胞肺癌脑转移 |
| Tyrosine Kinase Inhibitors Suppress Brain Metastases in Advanced Non-small Cell Lung Cancer |
| 投稿时间：2013-07-09 |
| DOI：10.11735/j.issn.1004-0242.2013.11.A017 |
|
 |
| 中文关键词: 肺癌 脑转移 酪氨酸激酶抑制剂 |
| 英文关键词:lung cancer brain metastasis tyrosine kinase inhibitors |
| 基金项目:武汉市重点攻关项目（201161038347） |
|
| 摘要点击次数: 2157 |
| 全文下载次数: 1089 |
| 中文摘要: |
| 摘 要：［目的］ 评价酪氨酸激酶抑制剂（tyrosine kinase inhibitors，TKI）对控制脑转移的作用。［方法］ 83例Ⅳ期（或复发）非小细胞肺癌（NSCLC）患者接受吉非替尼或厄洛替尼治疗，同期67例化疗患者作为对照，随访脑转移出现的时间和生存时间。［结果］ 经中位11.4个月的随访，TKI组脑转移发生率低于化疗组（18.29% vs 35.38%，χ2=5.5，P=0.019)。TKI组中发生脑转移的中位时间为7.6个月（6.9~8.3个月），明显长于单纯化疗组4.9个月（4.4~5.4个月）（χ2=15.6，P=0.001）。TKI组中位总生存时间为11.4个月（95%CI：10.3~12.6），长于单纯化疗组的7.5个月（95%CI：6.6~8.5）（χ2=19.3，P<0.001）。［结论］ TKI降低晚期NSCLC患者脑转移的风险，延长患者的生存时间。 |
| 英文摘要: |
| Abstract:［Purpose］ To investigate the effect of tyrosine kinase inhibitors on brain metastasis in patients with advanced non-small cell lung cancer. ［Methods］ Eighty-three patients with stage Ⅳ NSCLC treated with gefitinib or erlotinib and 67 patients treated with chemotherapy as control group were collected. The survival time and the time to brain metastasis were analyzed.［Results］ With a median follow-up of 11.4 months，the rate of brain metastasis in TKI group was lower than that in chemotherapy group（18.29% vs 35.38%，χ2=5.5，P=0.019). The median time to brain metastasis in TKI group was 7.6 months（95%CI:6.9~8.3），which was longer than that in chemotherapy group(4.9months，Log Rank χ2=15.6，P<0.001). The median overall survival time in TKI group was also longer than that in chemotherapy group(11.4 vs 7.5 months，χ2=19.3，P<0.001). ［Conclusions］ TKI(gefitinib or erlotinib) treatment reduces risk of BM and prolongs survival in patients with advanced NSCLC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |